GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cordlife Group Ltd (SGX:P8A) » Definitions » Net-Net Working Capital

Cordlife Group (SGX:P8A) Net-Net Working Capital : S$-0.09 (As of Jun. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Cordlife Group Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Cordlife Group's Net-Net Working Capital for the quarter that ended in Jun. 2024 was S$-0.09.

The industry rank for Cordlife Group's Net-Net Working Capital or its related term are showing as below:

SGX:P8A's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 4.95
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Cordlife Group Net-Net Working Capital Historical Data

The historical data trend for Cordlife Group's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cordlife Group Net-Net Working Capital Chart

Cordlife Group Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.15 -0.08 -0.05 -0.04 -0.04

Cordlife Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.04 -0.03 -0.04 -0.09

Competitive Comparison of Cordlife Group's Net-Net Working Capital

For the Diagnostics & Research subindustry, Cordlife Group's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cordlife Group's Price-to-Net-Net-Working-Capital Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Cordlife Group's Price-to-Net-Net-Working-Capital falls into.



Cordlife Group Net-Net Working Capital Calculation

Cordlife Group's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(65.009+0.75 * 22.672+0.5 * 0.797-92.805
-0-0.317)/256.308
=-0.04

Cordlife Group's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2024 is calculated as

Net-Net Working Capital(Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(59.54+0.75 * 23.986+0.5 * 0.914-101.272
-0-0.321)/256.308
=-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Cordlife Group  (SGX:P8A) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Cordlife Group Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Cordlife Group's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Cordlife Group Business Description

Traded in Other Exchanges
N/A
Address
1 Yishun Industrial Street 1, Number 06-01/09, A\'Posh Bizhub, Singapore, SGP, 768160
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Cordlife has processing and storage facilities in six key markets across Asia, namely Singapore, Hong Kong, Malaysia, India, Indonesia, and the Philippines. The company has two segments - The Banking segment, which comprises cord blood, cord lining, and cord tissue services. The Diagnostics segment comprises Metascreen, which is a non-invasive metabolic screening test specially designed for newborn babies, a non-invasive prenatal testing service and Eyescreen, a paediatric eye-screening service.

Cordlife Group Headlines

No Headlines